Literature DB >> 11439165

Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms.

M Djerbi1, T Darreh-Shori, B Zhivotovsky, A Grandien.   

Abstract

Death receptor-mediated apoptosis is involved in the regulation of immune responses and in the maintenance of immunological tolerance. FLICE-inhibitory proteins (FLIPs) are important modulators of death receptor-mediated apoptosis. To date, the FLIP family encompasses multiple members, of which some are reported to be antiapoptotic and others pro-apoptotic. This led us to investigate the activity of several FLIP proteins in vitro. Concomitant with the cloning of various FLIP isoforms, a new and unexpected member of the FLIP family, denoted FLIPR, was isolated from the human Burkitt lymphoma B-cell line Raji. During the characterization of FLIPR, the genomic sequence of human FLIP was found in the NCBI GenBank. This enabled us to present the complete exon-intron constellation of the human FLIP gene and the generation of all known human FLIP isoforms by alternative splicing. We show that the human FLIP gene with a size of approximately 48 kb, consists of at least 14 exons and can give rise to 11 distinct isoforms by alternative splicing. When studying the activity of some of these isoforms, including FLIPR, they all efficiently inhibited Fas-mediated apoptosis in A20 B lymphoma cells by impeding caspase-8, -3 and -7 activity as well as poly(ADP-ribose) polymerase (PARP) cleavage.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11439165     DOI: 10.1046/j.1365-3083.2001.00941.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  22 in total

1.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

2.  Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.

Authors:  Ali R Jazirehi; Dylan Arle
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

Review 3.  The therapeutic potential of TRAIL receptor signalling in cancer cells.

Authors:  R Yerbes; C Palacios; A López-Rivas
Journal:  Clin Transl Oncol       Date:  2011-12       Impact factor: 3.405

4.  Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Authors:  Shai J White; Laura M Kasman; Margaret M Kelly; Ping Lu; Laura Spruill; Paul J McDermott; Christina Voelkel-Johnson
Journal:  Free Radic Biol Med       Date:  2007-07-03       Impact factor: 7.376

5.  Activation-induced degradation of FLIP(L) is mediated via the phosphatidylinositol 3-kinase/Akt signaling pathway in macrophages.

Authors:  Bo Shi; Tri Tran; Rudina Sobkoviak; Richard M Pope
Journal:  J Biol Chem       Date:  2009-04-01       Impact factor: 5.157

6.  Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.

Authors:  Kari Högstrand; Eduar Hejll; Birgitta Sander; Björn Rozell; Lars-Gunnar Larsson; Alf Grandien
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

7.  Gene expression analysis implicates a death receptor pathway in schizophrenia pathology.

Authors:  Vibeke Sørensen Catts; Cynthia Shannon Weickert
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

8.  A sequence-based identification of the genes detected by probesets on the Affymetrix U133 plus 2.0 array.

Authors:  Jeremy Harbig; Robert Sprinkle; Steven A Enkemann
Journal:  Nucleic Acids Res       Date:  2005-02-18       Impact factor: 16.971

Review 9.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

10.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.